• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by GeneDx Holdings Corp. (Amendment)

    5/31/24 4:55:46 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $WGS alert in real time by email
    SC 13D/A 1 d11063208_13d-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 7)*

     

     

    GeneDx Holdings Corp.
    (Name of Issuer)

     

     

    Class A common stock, $0.0001 par value per share
    (Title of Class of Securities)

     

     

    81663L200
    (CUSIP Number)

     

    CMLS Holdings LLC

    Eli Casdin and Keith Meister

    c/o Corvex Management LP

    667 Madison Avenue

    New York, New York 10065

     

    (Name, Address and Telephone Number of Person Authorized to Receive

    Notices and Communications)

     

     

    May 29, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [  ].
       
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      CMLS Holdings LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      537,285 (1)(2)(3)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      537,285 (1)(2)(3)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      537,285 (1)(2)(3)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      2.1% (10)  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, OO  
         

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      C-LSH LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      537,285 (1)(2)(3)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      537,285 (1)(2)(3)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      537,285 (1)(2)(3)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      2.1% (10)  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, OO  
         

     

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      M-LSH LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      537,285 (1)(2)(3)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      537,285 (1)(2)(3)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      537,285 (1)(2)(3)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      2.1% (10)  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, OO  
         

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Capital, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      3,396,411 (5)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      3,396,411 (5)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      3,396,411 (5)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      13.0% (4)  

     

    14. TYPE OF REPORTING PERSON  
         
      IA  
         

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners FO1-MSV, LP  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      432,902 (5)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      432,902 (5)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      432,902 (5)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      1.7% (4)  

     

    14. TYPE OF REPORTING PERSON  
         
      PN  
         

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners Master Fund, L.P.  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      2,963,509 (5)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      2,963,509 (5)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      2,963,509 (5)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      11.3% (4)  

     

    14. TYPE OF REPORTING PERSON  
         
      PN  
         

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners GP, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      3,396,411 (5)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      3,396,411 (5)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      3,396,411 (5)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      13.0% (4)  

     

    14. TYPE OF REPORTING PERSON  
         
      OO  
         

     

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Eli Casdin  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      4,831 (7)(9)  

     

    8. SHARED VOTING POWER  
         
      3,933,696 (1)(2)(3)(5)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      4,831 (7)(9)  

     

    10. SHARED DISPOSITIVE POWER  
         
      3,933,696 (1)(2)(3)(5)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      3,938,527 (1)(2)(3)(5)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      14.9% (10)  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, IN  
         

     

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Keith A. Meister  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      OO  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      3,768 (8)(9)  

     

    8. SHARED VOTING POWER  
         
      3,011,066 (1)(2)(3)(6)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      3,768 (8)(9)  

     

    10. SHARED DISPOSITIVE POWER  
         
      3,011,066 (1)(2)(3)(6)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      3,014,834 (1)(2)(3)(6)(8)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      11.5% (10)  

     

    14. TYPE OF REPORTING PERSON  
         
      HC, IN  
         

     

     

     
     

     

    CUSIP No. 81663L200    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Corvex Management LP  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
        (b) [_]

      

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
    [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      2,473,781 (6)(9)  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      2,473,781 (6)(9)  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      2,473,781 (6)(9)  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
    [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      9.5% (4)  

     

    14. TYPE OF REPORTING PERSON  
         
      PN, IA  
         

     

     
     

     

     

    (1) Includes 333,144 shares of Class A common stock of GeneDx Holdings Corp. (the “Issuer”), par value $0.0001 per share (“Shares”).
    (2) Includes 204,141 Shares issuable upon the exercise of 204,141 private placement warrants of the Issuer. On September 3, 2021, each private placement warrant became exercisable to purchase one Share at a price of $379.50 per share, subject to adjustment, as described in the definitive proxy statement of the Issuer (File No. 001-39482) filed with the U.S. Securities Exchange Commission (the “SEC”) on July 2, 2021.
    (3) CMLS Holdings LLC is the record holder of the shares reported herein. The Board of Managers of CMLS Holdings LLC is comprised of Mr. Casdin and Mr. Meister who share voting and investment discretion with respect to the Shares held of record by CMLS Holdings LLC. C-LSH LLC and M-LSH LLC are the members of CMLS Holdings LLC, and Mr. Casdin and Mr. Meister are the managing members of C-LSH LLC and M-LSH LLC, respectively. As such, each of the foregoing may be deemed to have or share beneficial ownership of the Shares held directly by CMLS Holdings LLC.
    (4) Based on 26,150,866 Shares outstanding as of April 24, 2024, as reported in the Issuer’s Schedule 14A filed with the SEC on April 29, 2024. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of that person or entity, all shares subject to options, restricted stock units, or warrants held by such person or entity were deemed outstanding if such securities are currently vested, settled, or exercisable, or will vest, settle, or become exercisable. These shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person or entity.
    (5) Casdin Partners Master Fund, LP is the record holder of 2,963,509 shares reported herein. Casdin Partners FO1-MSV LP is the record holder of 432,902 shares reported herein. Casdin Capital, LLC is the investment adviser to Casdin Partners Master Fund, LP and Casdin Partners FO1-MSV LP, and Casdin Partners GP, LLC is the general partner of Casdin Partners Master Fund LP and Casdin Partners FO1-MSV LP. Eli Casdin is the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. As such, each of the foregoing may be deemed to have or share beneficial ownership of the Shares held directly by Casdin Partners Master Fund, LP and Casdin Partners FO1-MSV LP.
    (6) The shares reflected as beneficially owned by Mr. Meister include 2,473,781 Shares owned by investment funds advised by Corvex Management, L.P., which may be deemed to be indirectly beneficially owned by Keith Meister by virtue of Mr. Meister’s control of the general partner of Corvex Management, L.P.
    (7) Includes 3,066 shares issuable upon the exercise of fully vested options and 1,765 Shares that were issued upon the vesting of restricted stock units, in each case that were granted to Mr. Casdin in connection with his service on the board of directors of the Issuer. Does not include shares underlying 8,816 unvested options and 5,828 unvested restricted stock units.
    (8) Includes 2,391 shares issuable upon the exercise of fully vested options and 1,377 Shares that were issued upon the vesting of restricted stock units, in each case that were granted to Mr. Meister in connection with his service on the board of directors of the Issuer. Does not include shares underlying 8,816 unvested options and 5,828 unvested restricted stock units.

    (9) Share amounts have been adjusted to reflect the impact of a 1-for-33 reverse stock split of the Issuer’s Shares that became effective on May 4, 2023.

    (10)

    Based on 26,150,866 Shares outstanding as of April 24, 2024, as reported in the Issuer’s Schedule 14A filed with the SEC on April 29, 2024 and 204,141 Shares issuable upon the exercise of 204,141 private placement warrants of the Issuer. In computing the number of shares beneficially owned by a person or entity and the percentage ownership of that person or entity, all shares subject to options, restricted stock units, or warrants held by such person or entity were deemed outstanding if such securities are currently vested, settled, or exercisable, or will vest, settle, or become exercisable. These shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person or entity.

     
     

     

     

    This Amendment No. 7 (the “Amendment”) supplements the information set forth in the Schedule 13D (the “Schedule 13D”) filed with the United States Securities and Exchange Commission (the “SEC”) on August 2, 2021, as amended as of January 19, 2022, May 3, 2022, December 5, 2022, February 1, 2023, April 20, 2023, and November 17, 2023 by CMLS Holdings LLC, Keith Meister, Eli Casdin and the other Reporting Persons named therein, relating to the shares of Class A common stock, par value $0.0001 per share (“Shares”), of GeneDx Holdings Corp. (formerly known as Sema4 Holdings Corp., the “Issuer”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Schedule 13D.

     

    The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. Item 3 and 5 to the Schedule 13D are supplementally amended as follows. Information with respect to each Reporting Person is given solely by such Reporting Person and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person, except as otherwise provided in Rule 13d-1(k).

     

      

    Item 3. Source and Amount of Funds or Other Consideration.  
         
      The funds for the purchase of the Shares listed in Exhibit B came from the working capital of Casdin Partners Master Fund L.P., an investment fund advised by Casdin Capital LLC, of which Mr. Casdin is the managing member.  No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.      
         

      

    Item 5. Interest in Securities of the Issuer.
       
     

    The information set forth in this Schedule 13D with respect to the shared beneficial ownership of Common Stock by the Reporting Persons is incorporated by reference into this Item 5.

     

    The information set forth in Items 2, 3 and 4 is hereby incorporated by reference into this Item 5.

      

    Eli Casdin has the sole power to vote or direct the vote of 4,831 Shares and shared power to vote or to direct the vote and shared power to dispose or to direct the disposition of the 3,933,696 Shares.

     

    Keith Meister has the sole power to vote or to direct the vote and sole power to dispose or to direct the disposition of 3,768 Shares and shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 3,011,066 Shares.

      

    Each of CMLS, C-LSH and M-LSH shared power to vote or to direct the vote and shared power to dispose or to direct the disposition of the 537,285 Shares.

     

    Each of Casdin Capital, LLC and Casdin Partners GP, LLC has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 3,396,411 Shares.

     

    Casdin Partners Master Fund, L.P has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 2,963,509 Shares.

     

    Casdin Partners FO1-MSV, LP has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 432,902 Shares.

     

    Corvex Management LP has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of 2,473,781 Shares.

     

    The transactions by the Reporting Persons in the securities of the Issuer during the past sixty days are set forth in Exhibit B. All such transactions were carried out in open market transactions.

       

     

     

    Item 7. Material to be Filed as Exhibits.  

      

     

    Exhibit A: Joint Filing Agreement

    Exhibit B: Schedule of Transactions in Shares

         
     
     

     

     

    SIGNATURE

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

        May 31, 2024  
        (Date)  

     

     

    CMLS Holdings LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Manager
      (Name/Title)
       
     

    C-LSH LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
     

    M-LSH LLC*

     

    By: /s/ Keith A. Meister

      (Signature)
       
      Keith A. Meister, Managing Member
      (Name/Title)
       
     

    Casdin Capital, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     
     

     

     

     

    Casdin Partners Master Fund, L.P.

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin*
     

    Eli Casdin

     

      /s/ Keith A. Meister*
     

    Keith A. Meister

     

     

     

    Casdin Partners FO1-MSV, LP*

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Corvex Management LP*

     

    By: /s/ Keith Meister

      (Signature)
       
      Keith Meister, Managing Partner
      (Name/Title)

     

     

    * This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 10001).

     
     

     

     

    Exhibit A

     

     

    AGREEMENT

     

     

    The undersigned agree that this Schedule 13D amendment, dated May 31, 2024, relating to the Class A common stock, $0.0001 par value per share, of GeneDx Holdings Corp. shall be filed on behalf of the undersigned.

     

        May 31, 2024  
        (Date)  

     

     

    CMLS Holdings LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Manager
      (Name/Title)
       
     

    C-LSH LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
     

    M-LSH LLC

     

    By: /s/ Keith A. Meister

      (Signature)
       
      Keith A. Meister, Managing Member
      (Name/Title)
       
     

    Casdin Capital, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     
     

     

     

    Casdin Partners Master Fund, L.P.

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin
     

    Eli Casdin

     

      /s/ Keith A. Meister
     

    Keith A. Meister

     

     

     

    Casdin Partners FO1-MSV, LP

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Corvex Management LP

     

    By: /s/ Keith Meister

      (Signature)
       
      Keith Meister, Managing Partner
      (Name/Title)

     

     
     

     

    Exhibit B

     

     

    Schedule of Transactions in Shares

     

     

    Date of Transaction

     

    Reporting Person

     

    Title of Class

     

    Number of Shares Acquired

    Number of Shares Disposed

     

    Price Per

    Share

     

               
    5/13/2024 Casdin Partners Master Fund, L.P. Class A Common Stock 50,000   $23.3059
    5/23/2024 Casdin Partners Master Fund, L.P. Class A Common Stock 7,500   $19.5888 (1)
    5/24/2024 Casdin Partners Master Fund, L.P. Class A Common Stock 144,196   $20.1178 (2)
    5/28/2024 Casdin Partners Master Fund, L.P. Class A Common Stock 18,304   $20.6057
    5/29/2024 Casdin Partners Master Fund, L.P. Class A Common Stock 40,000   $21.0651 (3)

     

    (1) The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $19.5662 to $19.6341. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

     

    (2) The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $20 to $20.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

     

    (3) The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $20.9752 to $21.1876. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

     

    Get the next $WGS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WGS

    DatePrice TargetRatingAnalyst
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    10/20/2025$155.00Buy
    Canaccord Genuity
    7/9/2025$110.00Overweight
    Piper Sandler
    5/15/2025$88.00Buy
    Guggenheim
    5/9/2025$80.00Hold → Buy
    Jefferies
    8/28/2024$34.00Equal Weight
    Wells Fargo
    7/10/2024$43.00Buy
    Craig Hallum
    6/3/2024$21.00Hold
    Jefferies
    More analyst ratings

    $WGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in Health

    Recognition highlights growing global impact of rare disease diagnosis and the role of genomics in transforming health outcomes GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its President and Chief Executive Officer Katherine Stueland has been named to the TIME100 Health 2026 list – TIME's annual recognition of the 100 individuals who most influenced global health over the past year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211797482/en/TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most In

    2/11/26 9:05:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx (NASDAQ:WGS) is the global leader in r

    2/3/26 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

    Expects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit) Expects fourth quarter 2025 revenues of $121 million, with exome and genome revenue up 32% (43% excluding a one-time 2024 benefit) Expects full year 2025 exome and genome volume growth of more than 30%, with the fourth quarter 2025 accelerating to 34.3% Expects full year 2025 and fourth quarter 2025 adjusted gross margin of 71% Issues full year 2026 guidance expecting revenues between $540 and $555 million, with 33-35% exome and genome growth GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights,

    1/12/26 7:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Dechairo Bryan sold $510,874 worth of shares (5,961 units at $85.70), closing all direct ownership in the company (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    2/6/26 4:19:01 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Chief Operating Officer Dechairo Bryan converted options into 9,374 shares and sold $339,682 worth of shares (3,413 units at $99.53) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    2/3/26 7:30:38 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF FINANCIAL OFFICER Feeley Kevin sold $29,794 worth of shares (317 units at $93.99) and converted options into 754 shares, increasing direct ownership by 5% to 9,168 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    2/2/26 4:33:40 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $WGS
    SEC Filings

    View All

    $WGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Canaccord Genuity initiated coverage on GeneDx with a new price target

    Canaccord Genuity initiated coverage of GeneDx with a rating of Buy and set a new price target of $155.00

    10/20/25 8:45:12 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Piper Sandler initiated coverage on GeneDx with a new price target

    Piper Sandler initiated coverage of GeneDx with a rating of Overweight and set a new price target of $110.00

    7/9/25 8:30:02 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 144 filed by GeneDx Holdings Corp.

    144 - GeneDx Holdings Corp. (0001818331) (Subject)

    1/29/26 7:25:11 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GeneDx Holdings Corp. (0001818331) (Filer)

    1/12/26 5:10:50 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 144 filed by GeneDx Holdings Corp.

    144 - GeneDx Holdings Corp. (0001818331) (Subject)

    11/24/25 4:30:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $3,007,997 worth of shares (50,000 units at $60.16) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/16/25 4:00:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $5,600,994 worth of shares (100,000 units at $56.01) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/12/25 7:46:55 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    6/5/24 8:45:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Leadership Updates

    Live Leadership Updates

    View All

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer

    Renowned physician–scientist and healthcare innovator to lead GeneDx's vision for a new era of lifelong health informed by genomics GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx's vision to unlock the power of genomics to help every person live their healthiest life. As Chief Precision Medicine Officer, Dr. Lee will lead GeneDx's work to empower customizable precision medicine as the standard of care, leveraging the power of genomics to predict, prevent, and optimize health outcomes throughout a person's lifetime. Precision medicine c

    10/14/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

    Truveta co‑founder and longtime Microsoft leader joins Executive Leadership Team GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx's next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the company's long-term vision of enabling precision medicine. As Chief Business Officer, Gurry will architect and operate GeneDx's strategic business operations and partnership models that open doors and create opportunities t

    9/30/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Financials

    Live finance-specific insights

    View All

    GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx GeneDx (NASDAQ:WGS) is the global leader in r

    2/3/26 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

    Expects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit) Expects fourth quarter 2025 revenues of $121 million, with exome and genome revenue up 32% (43% excluding a one-time 2024 benefit) Expects full year 2025 exome and genome volume growth of more than 30%, with the fourth quarter 2025 accelerating to 34.3% Expects full year 2025 and fourth quarter 2025 adjusted gross margin of 71% Issues full year 2026 guidance expecting revenues between $540 and $555 million, with 33-35% exome and genome growth GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights,

    1/12/26 7:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

    Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume growth to 33% year-over-year Expanded adjusted gross margin to 74% and generated adjusted net income1 of $14.7 million for the third quarter 2025 Raised guidance to deliver between $425 and $428 million in revenue with between 53% to 55% full year growth in exome and genome revenue Granted FDA Breakthrough Device Designation for GeneDx ExomeDx™ and GenomeDx™ Leading the nation in genomic newborn screening (gNBS) as the sole commercial testing provider for new gNBS programs, including the NIH BEACONS initiative and Sunshine

    10/28/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/19/24 8:00:24 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/8/24 5:23:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology